Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
Petra Ross-Macdonald, Alice M Walsh, Scott D Chasalow, Ron Ammar, Simon Papillon-Cavanagh, Peter M Szabo, Toni K Choueiri, Mario Sznol, Megan Wind-Rotolo, Petra Ross-Macdonald, Alice M Walsh, Scott D Chasalow, Ron Ammar, Simon Papillon-Cavanagh, Peter M Szabo, Toni K Choueiri, Mario Sznol, Megan Wind-Rotolo
Abstract
Background: Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunotherapy, factors such as programmed death ligand-1 (PD-L1) status and tumor mutational burden show limited predictive utility in ccRCC. To address this gap, we report here the first molecular characterization of nivolumab response using paired index lesions, before and during treatment of metastatic ccRCC.
Methods: We analyzed gene expression and T-cell receptor (TCR) clonality using lesion-paired biopsies provided in the CheckMate 009 trial and integrated the results with their PD-L1/CD4/CD8 status, genomic mutation status and serum cytokine assays. Statistical tests included linear mixed models, logistic regression models, Fisher's exact test, and Kruskal-Wallis rank-sum test.
Results: We identified transcripts related to response, both at baseline and on therapy, including several that are amenable to peripheral bioassays or to therapeutic intervention. At both timepoints, response was positively associated with T-cell infiltration but not associated with TCR clonality, and some non-Responders were highly infiltrated. Lower baseline T-cell infiltration correlated with elevated transcription of Wnt/β-catenin signaling components and hypoxia-regulated genes, including the Treg chemoattractant CCL28. On treatment, analysis of the non-responding patients whose tumors were highly T-cell infiltrated suggests association of the RIG-I-MDA5 pathway in their nivolumab resistance. We also analyzed our data using previous transcriptional classifications of ccRCC and found they concordantly identified a molecular subtype that has enhanced nivolumab response but is sunitinib-resistant.
Conclusion: Our study describes molecular characteristics of response and resistance to nivolumab in patients with metastatic ccRCC, potentially impacting patient selection and first-line treatment decisions.
Trial registration number: NCT01358721.
Keywords: gene expression profiling; immunotherapy; kidney neoplasms; t-lymphocytes; tumor biomarkers.
Conflict of interest statement
Competing interests: PR-M, SDC, SP-C, PMS, RA, AMW, and MW-R were employees of Bristol Myers Squibb at the time of their contribution. TKC has served as a consultant/advisor for Pfizer, GlaxoSmithKline, Novartis, Merck, Bristol Myers Squibb, Bayer, Eisai, Roche, and Prometheus Labs, Inc, and has received institutional research funding from Pfizer, Novartis, GlaxoSmithKline, Bristol Myers Squibb, Merck, Exelixis, Roche, AstraZeneca, Peloton, and Tracon. MS has served as a consultant/advisor for Genentech-Roche, Bristol Myers Squibb, AstraZeneca/MedImmune, Pfizer, Novartis, Kyowa-Kirin, Amgen, Merus, Seattle Genetics, Immune Design, Prometheus, Anaeropharma, Astellas-Agensys, Immunova, Nektar, Neostem, Pierre-Fabre, Eli Lilly, Symphogen, Lion Biotechnologies, Amphivena, and Adaptive Biotechnologies.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Coppin C, Porzsolt F, Awa A, et al. . Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425. 10.1002/14651858.CD001425.pub2
- Thorsson V, Gibbs DL, Brown SD, et al. . The immune landscape of cancer. Immunity 2018;48:812–30. 10.1016/j.immuni.2018.03.023
- Cancer Genome Atlas Research Network . Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43–9. 10.1038/nature12222
- Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev 2018;70:127–37. 10.1016/j.ctrv.2018.07.009
- McDermott DF, Huseni MA, Atkins MB, et al. . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24:749–57. 10.1038/s41591-018-0053-3
- Beuselinck B, Job S, Becht E, et al. . Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res 2015;21:1329–39. 10.1158/1078-0432.CCR-14-1128
- Hakimi AA, Voss MH, Kuo F, et al. . Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial. Cancer Discov 2019;9:510–25. 10.1158/-18-0957
- Cristescu R, Mogg R, Ayers M, et al. . Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018;362. 10.1126/science.aar3593. [Epub ahead of print: 12 Oct 2018].
- Verbiest A, Renders I, Caruso S, et al. . Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors. Clin Genitourin Cancer 2019;17:e981–94. 10.1016/j.clgc.2019.05.009
- Ascierto ML, McMiller TL, Berger AE, et al. . The intratumoral balance between metabolic and immunologic gene expression is associated with anti-PD-1 response in patients with renal cell carcinoma. Cancer Immunol Res 2016;4:726–33. 10.1158/2326-6066.CIR-16-0072
- Choueiri TK, Albiges L, Haanen JBAG, et al. . Biomarker analyses from javelin renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol 2019;37:101. 10.1200/JCO.2019.37.15_suppl.101
- Choueiri TK, Fishman MN, Escudier B, et al. . Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res 2016;22:5461–71. 10.1158/1078-0432.CCR-15-2839
- Choueiri TK, Fishman MN, Escudier B, et al. . Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes. J Clin Oncol 2015;33:4500. 10.1200/jco.2015.33.15_suppl.4500
- Miao D, Margolis CA, Gao W, et al. . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 2018;359:801–6. 10.1126/science.aan5951
- Pinheiro JBD, DebRoy S, Sarkar D. R core team. nlme: linear and nonlinear mixed effects models. R package version 3.1-109, 2020.
- Ritchie ME, Phipson B, Wu D, et al. . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47. 10.1093/nar/gkv007
- Tilford CA, Siemers NO. Gene set enrichment analysis. : Nikolsky Y, Bryant J, . Protein networks and pathway analysis. Methods in molecular biology. 563. Totawa, NJ: Humana Press, 2009: 99–121.
- Subramanian A, Tamayo P, Mootha VK, et al. . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–50. 10.1073/pnas.0506580102
- Liberzon A, Birger C, Thorvaldsdóttir H, et al. . The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 2015;1:417–25. 10.1016/j.cels.2015.12.004
- Abbas AR, Baldwin D, Ma Y, et al. . Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 2005;6:319–31. 10.1038/sj.gene.6364173
- Ji R-R, Chasalow SD, Wang L, et al. . An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61:1019–31. 10.1007/s00262-011-1172-6
- Lugrin J, Martinon F. The AIM2 inflammasome: sensor of pathogens and cellular perturbations. Immunol Rev 2018;281:99–114. 10.1111/imr.12618
- Braun DA, Hou Y, Bakouny Z, et al. . Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med 2020;26:909–18. 10.1038/s41591-020-0839-y
- Kessenbrock K, Dijkgraaf GJP, Lawson DA, et al. . A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell 2013;13:300–13. 10.1016/j.stem.2013.06.005
- Sznol M, Fishman M, Escudier B, et al. . Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer 2015;3:P197. 10.1186/2051-1426-3-S2-P197
- Facciabene A, Peng X, Hagemann IS, et al. . Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011;475:226–30. 10.1038/nature10169
- Mohan T, Deng L, Wang B-Z. CCL28 chemokine: an anchoring point bridging innate and adaptive immunity. Int Immunopharmacol 2017;51:165–70. 10.1016/j.intimp.2017.08.012
- Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 2019;38:65–77. 10.1007/s10555-019-09799-0
- Elvidge GP, Glenny L, Appelhoff RJ, et al. . Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 2006;281:15215–26. 10.1074/jbc.M511408200
- Abril-Rodriguez G, Torrejon DY, Liu W, et al. . PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer 2020;1:46–58. 10.1038/s43018-019-0003-0
- Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. . A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101–9. 10.1084/jem.184.3.1101
- Qiu L, Wang T, Tang Q, et al. . Long non-coding RNAs: regulators of viral infection and the interferon antiviral response. Front Microbiol 2018;9:1621. 10.3389/fmicb.2018.01621
- Ayers M, Lunceford J, Nebozhyn M, et al. . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017;127:2930–40. 10.1172/JCI91190
- Willingham S, Hotson AN, Laport G, et al. . Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444. Ann Oncol 2018;29:viii403–4. 10.1093/annonc/mdy288.010
- Thibodeau BJ, Fulton M, Fortier LE, et al. . Characterization of clear cell renal cell carcinoma by gene expression profiling. Urol Oncol 2016;34:168.e1–168.e9. 10.1016/j.urolonc.2015.11.001
- Wang L, Saci A, Szabo PM, et al. . EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 2018;9:3503. 10.1038/s41467-018-05992-x
- McDermott DF, Sosman JA, Sznol M, et al. . Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 2016;34:833–42. 10.1200/JCO.2015.63.7421
- Lee C-H, Motzer RJ, Glen H, et al. . Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. Br J Cancer 2020. 10.1038/s41416-020-01092-0. [Epub ahead of print: 07 Oct 2020].
- Marçais A, Viel S, Grau M, et al. . Regulation of mouse NK cell development and function by cytokines. Front Immunol 2013;4:450. 10.3389/fimmu.2013.00450
- Hu Y, Wu L, Wang C, et al. . Swainsonine exposure induces impairment of host immune response in pregnant BALB/c mice. BMC Immunol 2015;16:53. 10.1186/s12865-015-0114-z
- Goss PE, Reid CL, Bailey D, et al. . Phase Ib clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin Cancer Res 1997;3:1077–86.
- Whelan S, Ophir E, Kotturi MF, et al. . PVRIG and PVRL2 are induced in cancer and inhibit CD8+ T-cell function.. Cancer Immunol Res 2019;7:257–68. 10.1158/2326-6066.CIR-18-0442
- Liang S, Levy O, Ganguly S, et al. . Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer. J Clin Oncol 2017;35:3074. 10.1200/JCO.2017.35.15_suppl.3074
- Nishi A, Numata S, Tajima A, et al. . De novo non-synonymous TBL1XR1 mutation alters Wnt signaling activity. Sci Rep 2017;7:2887. 10.1038/s41598-017-02792-z
- Galluzzi L, Spranger S, Fuchs E, et al. . Wnt signaling in cancer immunosurveillance. Trends Cell Biol 2019;29:44–65. 10.1016/j.tcb.2018.08.005
- Choueiri TK, Plimack ER, Bauer TM, et al. . Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). J Clin Oncol 2020;38:611. 10.1200/JCO.2020.38.6_suppl.611
- Chamie K, Donin NM, Klöpfer P, et al. . Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol 2017;3:913–20. 10.1001/jamaoncol.2016.4419
- Selby MJ, Engelhardt JJ, Quigley M, et al. . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013;1:32–42. 10.1158/2326-6066.CIR-13-0013
- Jacquelot N, Yamazaki T, Roberti MP, et al. . Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res 2019;29:846–61. 10.1038/s41422-019-0224-x
- Heidegger S, Wintges A, Stritzke F. Rig-I activation is critical for responsiveness to checkpoint blockade. Sci Immunol 2019;410.1126/sciimmunol.aau8943. [Epub ahead of print: 13 Sep 2019].
Source: PubMed